Improvement of Glucose Tolerance in NIDDM by Clofibrate Randomized Double-Blind Study
| Autor: | Shigeaki Baba, Yasue Omori, Yukimasa Hirata, Nobuo Sakamoto, Seiki Nambu, Masashi Kobayashi, Yukio Shigeta |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Blood Glucose
medicine.medical_specialty Erythrocytes endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment Placebo Fasting glucose Double blind study Random Allocation Double-Blind Method Diabetes mellitus Internal medicine Internal Medicine medicine Humans Clofibrate Triglycerides Advanced and Specialized Nursing Clinical Trials as Topic biology business.industry Insulin nutritional and metabolic diseases Insulin sensitivity Glucose Tolerance Test medicine.disease Receptor Insulin Insulin receptor Endocrinology Diabetes Mellitus Type 2 biology.protein business medicine.drug |
| Zdroj: | Diabetes Care. 11:495-499 |
| ISSN: | 1935-5548 0149-5992 |
| Popis: | A randomized double-blind study was performed to examine the effect of clofibrate on glucose tolerance in subjects with non-insulin-dependent diabetes mellitus (NIDDM). Clofibrate (1.5 g/day) or placebo was administered to 70 patients and an oral glucose tolerance test (OGTT) was performed before and 12 wk after treatment. Blood glucose levels were significantly improved in clofibrate-treated groups at all time points during OGTT, whereas there was no change in insulin levels. Improvement of fasting glucose levels required 8 wk of clofibrate treatment. Insulin binding to erythrocytes demonstrated no significant change in the clofibrate-treated subjects.A randomized double-blind study was performed to examine the effect of clofibrate on glucose tolerance in subjects with non-insulin-dependent diabetes mellitus (NIDDM). Clofibrate (1.5 g/day) or placebo was administered to 70 patients and an oral glucose tolerance test (OGTT) was performed before and 12 wk after treatment. Blood glucose levels were significantly improved in clofibrate-treated groups at all time points during OGTT, whereas there was no change in insulin levels. Improvement of fasting glucose levels required 8 wk of clofibrate treatment. Insulin binding to erythrocytes demonstrated no significant change in the clofibrate-treated subjects. These results suggest that clofibrate improves glucose tolerance in NIDDM subjects without a change in insulin receptors and that clofibrate increases insulin sensitivity through an unknown postreceptor mechanism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|